Form 8-K - Current report:
SEC Accession No. 0000950170-25-043485
Filing Date
2025-03-24
Accepted
2025-03-24 07:01:55
Documents
13
Period of Report
2025-03-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lxeo-20250324.htm   iXBRL 8-K 59298
2 EX-99.1 lxeo-ex99_1.htm EX-99.1 164162
3 GRAPHIC img46940271_0.jpg GRAPHIC 249092
  Complete submission text file 0000950170-25-043485.txt   695146

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20250324.xsd EX-101.SCH 25989
15 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20250324_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 25762195
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)